Concord Biotech credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
0.00.00.46.2
−416−416−317−284
−0.21×−0.21×−0.18×−0.19×
0.00×0.00×0.00×0.01×
−1.03×−1.13×−0.63×−0.66×
1,034.40×1,034.40×853.88×148.11×
0.0%0.0%0.0%0.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CONCORDBIO₹1,230.60

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹12,874 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt—6.20.40.00.0
Net Debt—-284.5-317.3-415.6-415.6
Net Debt/Equity—-0.19-0.18-0.21-0.21
Total Debt/EBITDA—0.010.000.000.00
Net Debt/EBITDA—-0.66-0.63-1.13-1.03
Interest Coverage (EBIT/Interest)—148.11853.881,034.401,034.40
Total Debt/Total Capital %—0.410.020.000.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.